Related Experiment Video

Updated: May 25, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Current treatment options and response rates in children with chronic hepatitis C

Stefan Wirth

    World Journal of Gastroenterology
    |January 19, 2012
    PubMed

    Insights

    Hepatitis C virus (HCV) vertical transmission is common in children. PEG-interferon and ribavirin treatment shows high efficacy, especially for genotypes 2/3, offering a well-tolerated standard of care.

    Area of Science:

    • Hepatology
    • Pediatric Infectious Diseases
    • Virology

    Background:

    • Vertical transmission is the primary route of Hepatitis C Virus (HCV) infection in children, with perinatal transmission rates between 2-5%.
    • Prevalence of HCV in children in developed nations is between 0.1-0.4%, with spontaneous viral clearance varying by genotype (2.4%-25%).

    Discussion:

    • A combination therapy of recombinant polyethylene glycol (PEG)-interferon α and ribavirin is approved for children aged 2-17 years with chronic HCV.
    • Prospective studies involving 318 children and adolescents (3-17 years) demonstrated an overall sustained viral response (SVR) of 60.7%.

    Key Insights:

    • SVR rates varied by genotype: 51% for genotype 1, 93% for genotype 2/3, and 55% for genotype 4.
    • Treatment was generally well-tolerated, with notable side effects in approximately 20% of patients.
    • The PEG-interferon α and ribavirin combination is effective and well-tolerated, particularly for genotype 2/3 infections.

    Outlook:

    • This combination therapy is recommended as the standard of care for pediatric HCV patients.
    • Further research is needed to identify more effective treatment options for genotype 1 infections in children.

    Keywords:
    ChildrenChronic hepatitis CPolyethylene glycol-interferon and ribavirinResponse rateTreatment

    More Related Videos

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

    Published on: September 30, 2021

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...